Clinical remission as measured by a decrease in intact parathyroid hormone levels after administration of cinacalcet in patients with severe hyperparathyroidism.

1. Fouque D, Vennegar M, ter Wee P et al. EBPG guidelines on nutrition 4): recommendation for vitamins, minerals and trace elements administration in MHD patients. Nephrol Dial Transplant 2007; 22(s2): ii62–ii70 2. Maccarrone M, Manca di Villahermosa S, Giacominelli Stuffler R et al. Vitamin E, 5-lipoxygenase and kidney disease. In: Bellock OH (ed.) New Topics in Vitamin E Research New York: Nova Science Publishers, 2007; 111–132 3. Badiou S, Cristol JP, Morena M et al. Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients. Int J Vitam Nutr Res 2003; 73: 290–296 4. Singh U, Devaraj S, Jalal I. Vitamin E, oxidative stress and inflammation. Annu Rev Nutr 2005; 25: 151–174 5. Taccone Gallucci M, Manca di Villahermosa S, Battistini L et al. N-3 PUFAs reduce oxidative stress in ESRD patients by inhibiting 5-lipoxygenase activity. Kidney Int 2006; 69: 1450–1454 6. Munteanu A, Zingg JM, Azzi A. Anti-atherosclerotic effects of vitamin E: myth or reality? J Cell Mol Med 2004; 8: 59–76 7. Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: metaanalysis of randomised trials. Lancet 2003; 361: 2017–2023 8. Himmelfarb J, Kane J, McMonagle E et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 2003; 64: 978–991